Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients

Flaminia Olearo; Ilona Kronig; Stavroula Masouridi-Levrat; Yves Chalandon; Nina Khanna; Jakob Passweg; Michael Medinger; Nicolas J Mueller; Urs Schanz; Christian Van Delden; Dionysios Neofytos

doi:10.1093/ofid/ofaa246

Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients

Open Forum Infect Dis. 2020 Jun 23;7(7):ofaa246. doi: 10.1093/ofid/ofaa246. eCollection 2020 Jul.

Authors

Affiliations

¹ Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.
² Institute for Medical Microbiology, Virology and Hygiene, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
³ Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
⁴ Division of Infectious Diseases, University Hospital of Basel, Basel, Switzerland.
⁵ Department of Hematology, Bone Marrow Transplant Unit, University Hospital of Basel, Basel, Switzerland.
⁶ Division of Infectious Diseases and Hospital Epidemiology, Zurich, Switzerland.
⁷ Department of Hematology, Bone Marrow Transplant Unit, University Hospital of Zurich, Zurich, Switzerland.

Abstract

In a large, multicenter, contemporary, 8-year, cohort study, one third of allogeneic-hematopoietic cell transplant (HCT) recipients with Pseudomonas aeruginosa (PSA) infection developed a recurrent infection within 3 months. Antibiotic treatment duration of ≥14 days was the only significantly associated variable with reduced recurrence rates of PSA infections in allogeneic-HCT recipients.

Keywords: Pseudomonas aeruginosa; allogeneic hematopoietic cell transplant recipients; duration treatment; recurrent infection.